Neophyr 225 ppm mol/mol, medicinal gas, compressed Ireland - English - HPRA (Health Products Regulatory Authority)

neophyr 225 ppm mol/mol, medicinal gas, compressed

sol s.p.a. - nitric oxide - medicinal gas, compressed - 225 ppm mole(s) - other respiratory system products; nitric oxide

Neophyr 1000 ppm mol/mol, medicinal gas, compressed Ireland - English - HPRA (Health Products Regulatory Authority)

neophyr 1000 ppm mol/mol, medicinal gas, compressed

sol s.p.a. - nitric oxide - medicinal gas, compressed - 1000 ppm mole(s) - other respiratory system products; nitric oxide

Neophyr 450 ppm mol/mol, medicinal gas, compressed Ireland - English - HPRA (Health Products Regulatory Authority)

neophyr 450 ppm mol/mol, medicinal gas, compressed

sol s.p.a. - nitric oxide - medicinal gas, compressed - 450 ppm mole(s) - other respiratory system products; nitric oxide

Broncho-Vaxom Malta - English - Medicines Authority

broncho-vaxom

om pharma s.a. r. da industria, 2, 2610-088 amadora, lisboa, portugal - lyophilized bacterial, lysates - capsule - lyophilized bacterial lysates 7 mg - other respiratory system products

Broncho-Vaxom Malta - English - Medicines Authority

broncho-vaxom

om pharma s.a. r. da industria, 2, 2610-088 amadora, lisboa, portugal - lyophilized bacterial, lysates - capsule - lyophilized bacterial lysates 3.5 mg - other respiratory system products

INOmax European Union - English - EMA (European Medicines Agency)

inomax

linde healthcare ab - nitric oxide - hypertension, pulmonary; respiratory insufficiency - other respiratory system products - inomax, in conjunction with ventilatory support and other appropriate active substances, is indicated:for the treatment of newborn infants ≥34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.

KALYDECO TABLET Canada - English - Health Canada

kalydeco tablet

vertex pharmaceuticals (canada) incorporated - ivacaftor - tablet - 150mg - ivacaftor 150mg - cystic fibrosis transmembrane conductance regulator potentiators

KALYDECO GRANULES Canada - English - Health Canada

kalydeco granules

vertex pharmaceuticals (canada) incorporated - ivacaftor - granules - 50mg - ivacaftor 50mg - cystic fibrosis transmembrane conductance regulator potentiators

KALYDECO GRANULES Canada - English - Health Canada

kalydeco granules

vertex pharmaceuticals (canada) incorporated - ivacaftor - granules - 75mg - ivacaftor 75mg - cystic fibrosis transmembrane conductance regulator potentiators

ORKAMBI TABLET Canada - English - Health Canada

orkambi tablet

vertex pharmaceuticals (canada) incorporated - ivacaftor; lumacaftor - tablet - 125mg; 200mg - ivacaftor 125mg; lumacaftor 200mg - cystic fibrosis transmembrane conductance regulator correctors